Patent Owner's Current List of Exhibits | Aug 4, 2025 | PAPER | PATENT OWNER |
Exhibit 2001 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2002 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2003 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2004 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2005 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2006 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2007 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2008 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2009 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2010 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2011 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2012 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2013 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2014 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2015 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2016 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2017 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2018 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2019 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2020 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2021 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2022 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2023 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2024 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2025 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2026 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2027 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2028 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2029 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2030 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2031 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2032 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2033 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2034 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2035 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Patent Owner's Brief Requesting Discretionary Denial of Institution | Aug 4, 2025 | PAPER | PATENT OWNER |
Notice: Notice filing date accorded | Jun 4, 2025 | PAPER | BOARD |
Power of Attorney for Patent Owner Helsinn Healthcare S.A. | May 22, 2025 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | May 22, 2025 | PAPER | PATENT OWNER |
US8623826 to F. Trento et al. | May 1, 2025 | EXHIBIT | PETITIONER |
US9186357 to F. Trento et al. | May 1, 2025 | EXHIBIT | PETITIONER |
US9943515 to F. Trento et al. | May 1, 2025 | EXHIBIT | PETITIONER |
US10828297 to F. Trento et al. | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 13/077,462 - Part 1 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 13/077,462 - Part 2 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 14/069,927 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 15/003,327 - Part 1 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 15/003,327 - Part 2 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 15/923,050 | May 1, 2025 | EXHIBIT | PETITIONER |
J. Herrstedt & P. Dombernowsky, Anti-Emetic Therapy in Cancer Chemotherapy: | May 1, 2025 | EXHIBIT | PETITIONER |
T. Hoffmann et al., Design and synthesis of a novel, achiral class of highl | May 1, 2025 | EXHIBIT | PETITIONER |
R. Hargreaves, Imaging Substance P Receptors (NK1) in the Living Human Brai | May 1, 2025 | EXHIBIT | PETITIONER |
The Antiemetic Subcommittee of the Multinational Association of Supportive | May 1, 2025 | EXHIBIT | PETITIONER |
M. Bös et al., 4-phenyl-pyridine derivatives, U.S. Patent 6,297,375 B1 (iss | May 1, 2025 | EXHIBIT | PETITIONER |
Eisai, Inc., ALOXI (palonosetron HCl) Capsules, package insert (Aug. 2008) | May 1, 2025 | EXHIBIT | PETITIONER |
J.D. Herrington et al., Randomized, Placebo-controlled, Pilot Study Evaluat | May 1, 2025 | EXHIBIT | PETITIONER |
D. Bonadeo et al., WO 2008/04955 - Soft Capsules Comprising Palonosetron Hy | May 1, 2025 | EXHIBIT | PETITIONER |
R.J. Gralla et al., Recommendations for the use of antiemetics: evidence-ba | May 1, 2025 | EXHIBIT | PETITIONER |
K. Jordan et al., Guidelines for Antiemetic Treatment of Chemotherapy-Induc | May 1, 2025 | EXHIBIT | PETITIONER |
Curriculum Vitae of Dr. Stephen J. Peroutka | May 1, 2025 | EXHIBIT | PETITIONER |
G.K. Reddy et al., Novel Neurokinin-1 Antagonists as Antiemetics for the Tr | May 1, 2025 | EXHIBIT | PETITIONER |
M.S. Aapro et al., A phase III, double-blind, randomized trial of palonoset | May 1, 2025 | EXHIBIT | PETITIONER |
D. Campos et al., Prevention of cisplatin-induced emesis by the oral neurok | May 1, 2025 | EXHIBIT | PETITIONER |
A.E. Chang et al., eds., Oncology: An Evidence-Based Approach (2006) | May 1, 2025 | EXHIBIT | PETITIONER |
S.P. Chawla et al., Establishing the Dose of the Oral NK1 Antagonist Aprepi | May 1, 2025 | EXHIBIT | PETITIONER |
S.P. Chawla et al., Establishing the Dose of the Oral NK1 Antagonist Aprepi | May 1, 2025 | EXHIBIT | PETITIONER |
A. De Leon, Palonosetron (Aloxi): a second-generation 5-HT3 receptor antago | May 1, 2025 | EXHIBIT | PETITIONER |
R.A. Duffy, Potential therapeutic targets for neurokinin-1 receptor antagon | May 1, 2025 | EXHIBIT | PETITIONER |
Press Release, Eisai Co., FDA Approves ALOXIⓇ (Palonosetron HCl) Capsules | May 1, 2025 | EXHIBIT | PETITIONER |
Merck & Co., EMEND, package insert (2008) | May 1, 2025 | EXHIBIT | PETITIONER |
DailyMed, EMEND (aprepitant) Capsule, https://web.archive.org/web/200902021 | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, General Considerations for the Clinical | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, Q3A Impurities in New Drug Substances (2 | May 1, 2025 | EXHIBIT | PETITIONER |
D.G. Warr et al., Efficacy and tolerability of aprepitant for the preventio | May 1, 2025 | EXHIBIT | PETITIONER |
S.M. Grunberg et al., Effectiveness of a single-day three-drug regimen of d | May 1, 2025 | EXHIBIT | PETITIONER |
Press Release, GSK provides update on regulatory filings for Zunrisa/Rezoni | May 1, 2025 | EXHIBIT | PETITIONER |
P.J. Hesketh et al., The Oral Neurokinin-1 Antagonist Aprepitant for the Pr | May 1, 2025 | EXHIBIT | PETITIONER |
G.S. Paulekuhn et al., Trends in active pharmaceutical ingredient salt sele | May 1, 2025 | EXHIBIT | PETITIONER |
S. Poli-Bigelli et al., Addition of the neurokinin 1 receptor antagonist ap | May 1, 2025 | EXHIBIT | PETITIONER |
T. Qiu et al., Antiemetic regimen with aprepitant in the prevention of chem | May 1, 2025 | EXHIBIT | PETITIONER |
C. Rojas, The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits su | May 1, 2025 | EXHIBIT | PETITIONER |
C. Ruhlmann & J. Herrstedt, Casopitant: a novel NK1-receptor antagonist in | May 1, 2025 | EXHIBIT | PETITIONER |
R. Saito et al., Roles of substance P and NK1 receptor in the brainstem in | May 1, 2025 | EXHIBIT | PETITIONER |
Ronald D. Schoenwald, Pharmacokinetics in Drug Discovery and Development (2 | May 1, 2025 | EXHIBIT | PETITIONER |
A.G. Thomas, Netupitant and palonosetron trigger NK1 receptor internalizati | May 1, 2025 | EXHIBIT | PETITIONER |
K.E. Thummel, Gut instincts: CYP3A4 and intestinal drug metabolism, 117(11) | May 1, 2025 | EXHIBIT | PETITIONER |
D.S. Wang, Effect of aprepitant for the prevention of chemotherapy-induced | May 1, 2025 | EXHIBIT | PETITIONER |
W. Yeo et al., A randomized study of aprepitant, ondansetron and dexamethas | May 1, 2025 | EXHIBIT | PETITIONER |
S.F. Zhou, Drugs Behave as Substrates, Inhibitors and Inducers of Human Cyt | May 1, 2025 | EXHIBIT | PETITIONER |
Parenteral, Merriam-Webster, https://www.merriam-webster.com/dictionary/par | May 1, 2025 | EXHIBIT | PETITIONER |
NK1 receptor antagonist by Roche, Advances in Drug Discovery (Feb. 23, 2006 | May 1, 2025 | EXHIBIT | PETITIONER |
RxList, ALOXI (palonosetron HCl) Capsules, https://web.archive.org/web/2008 | May 1, 2025 | EXHIBIT | PETITIONER |
DailyMed excerpts relating to ALOXI (palonosetron HCl) Capsules, downloaded | May 1, 2025 | EXHIBIT | PETITIONER |
DailyMed excerpts relating to Aloxi (palonosetron HCl) Capsules, as archive | May 1, 2025 | EXHIBIT | PETITIONER |
PCT Publication WO 2011/061622, filed 18 November 2010 | May 1, 2025 | EXHIBIT | PETITIONER |
Provisional Patent Appl. 61/382,709, filed 14 September 2010 | May 1, 2025 | EXHIBIT | PETITIONER |
Provisional Patent Appl. 61/262,470, filed 18 November 2009 | May 1, 2025 | EXHIBIT | PETITIONER |
Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/ | May 1, 2025 | EXHIBIT | PETITIONER |
P. Li & L. Zhao, Developing Early Formulations: Practice and Perspective, 3 | May 1, 2025 | EXHIBIT | PETITIONER |
G. Sanso, Double capsule for the administration of active principles in mul | May 1, 2025 | EXHIBIT | PETITIONER |
B. Cromie, Drug Combinations, 1(2) Current Medical Research and Opinion 78 | May 1, 2025 | EXHIBIT | PETITIONER |
Notice: Power of Attorney | May 1, 2025 | PAPER | PETITIONER |
Expert Declaration of Dr. Stephen J. Peroutka | May 1, 2025 | EXHIBIT | PETITIONER |
Petition: as filed | May 1, 2025 | PAPER | PETITIONER |
SIGNED Statement - Trento'357 Petitions | May 1, 2025 | PAPER | PETITIONER |